Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
17 pending office actions • 13 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
University of Iowa Research Foundation has 17 pending office actions in Biotechnology & Pharmaceuticals. Those matters span 16 examiners and 13 art units, showing a broad prosecution footprint across the technology area. The near one-to-one relationship between actions and examiners means the portfolio is not centered on a single examiner or a narrow examination channel.
RONEY, CELESTE A is the busiest examiner, with 2 pending matters. That limited concentration contrasts with the overall spread of the docket, so a centralized response strategy may need to be supplemented by examiner-specific preparation. The art-unit distribution also indicates that claim issues and procedural expectations may vary materially among applications.
Counsel should maintain matter-level tracking for deadlines, interview opportunities, and recurring claim themes. The breadth of assignments makes consistent invention narratives and coordinated amendment positions useful, while preserving flexibility for differences in examiner treatment.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (29%) |
| §103 only | 3 (18%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 3 (18%) |
| Multi-statute (no §101) | 5 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 2 | 63.0% | +17.4% |
| PORTILLO, JAIRO H | 1 | 53.4% | +30.7% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| OGLES, MATTHEW ERIC | 1 | 50.0% | +58.4% |
| NGUYEN, JOHN P | 1 | 43.9% | +41.8% |
| PAK, JOHN D | 1 | 52.3% | +37.8% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18211108 | Apparatus, Systems and Methods for Predicting, Screening and Monitoring of Encephalopathy/Delirium | OGLES, MATTHEW ERIC | 133d overdue |
| 18434313 | SIMULTANEOUS AND CONTINUOUS MEASUREMENT OF OTOACOUSTIC EMISSIONS ACROSS LEVEL AND FREQUENCY | PORTILLO, JAIRO H | 17d overdue |
| 17503082 | MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS | REDDY, SUNITA | 5d |
| 18572054 | SUSTAINED RELEASE FORMULATIONS COMPRISING A SELECTIVE ANDROGEN RECEPTOR MODULATOR | BAEK, BONG-SOOK | 22d |
| 18031760 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | WESTERBERG, NISSA M | 53d |
| 18550659 | PATHOGEN MOIETIES AND USES THEREOF | DUFFY, PATRICIA ANN | — |
| 18270162 | SENSE,SUPPRESSOR TRANSFER RNA COMPOSITIONS AND RELATED USES AND FUNCTIONS | GROOMS, TIFFANY NICOLE | — |
| 18256593 | COMPOSITIONS COMPRISING MOLECULES FOR CYSTIC FIBROSIS TREATMENT | NGUYEN, JOHN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18211108 | Apparatus, Systems and Methods for Predicting, Screening and Monitoring of Encephalopathy/Delirium | OGLES, MATTHEW ERIC | 133d overdue |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | ALSOMAIRY, SARAH ABDOALATIF | 23d overdue |
| 18434313 | SIMULTANEOUS AND CONTINUOUS MEASUREMENT OF OTOACOUSTIC EMISSIONS ACROSS LEVEL AND FREQUENCY | PORTILLO, JAIRO H | 17d overdue |
| 18572054 | SUSTAINED RELEASE FORMULATIONS COMPRISING A SELECTIVE ANDROGEN RECEPTOR MODULATOR | BAEK, BONG-SOOK | 22d |
| 18031760 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | WESTERBERG, NISSA M | 53d |
| 18886316 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | RONEY, CELESTE A | — |
| 18886318 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | RONEY, CELESTE A | — |
| 18550659 | PATHOGEN MOIETIES AND USES THEREOF | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 3791 | 4 |
| 1612 | 2 |
| 1611 | 1 |
| 1645 | 1 |
| 1646 | 1 |
| 1637 | 1 |
| 1619 | 1 |
| 1699 | 1 |
| 1618 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18886316 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | RONEY, CELESTE A | 1612 | §103DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18886318 | GENOTYPE-AGNOSTIC RESCUE OF CYSTIC FIBROSIS WITH SMALL MOLECULE BICARBONATE CHANNELS | RONEY, CELESTE A | 1612 | §103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18434313 | SIMULTANEOUS AND CONTINUOUS MEASUREMENT OF OTOACOUSTIC EMISSIONS ACROSS LEVEL AND FREQUENCY | PORTILLO, JAIRO H | 3791 | §101§103 | Final Rejection | 17d overdue | Pending | Feb 06, 2024 |
| 18572054 | SUSTAINED RELEASE FORMULATIONS COMPRISING A SELECTIVE ANDROGEN RECEPTOR MODULATOR | BAEK, BONG-SOOK | 1611 | §103§112 | Final Rejection | 22d | Pending | Dec 19, 2023 |
| 18550659 | PATHOGEN MOIETIES AND USES THEREOF | DUFFY, PATRICIA ANN | 1645 | §102§103 | Final Rejection | — | Pending | Sep 14, 2023 |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112 | Final Rejection | 23d overdue | Pending | Aug 29, 2023 |
| 18270162 | SENSE,SUPPRESSOR TRANSFER RNA COMPOSITIONS AND RELATED USES AND FUNCTIONS | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18211108 | Apparatus, Systems and Methods for Predicting, Screening and Monitoring of Encephalopathy/Delirium | OGLES, MATTHEW ERIC | 3791 | §101§112 | Non-Final OA | 133d overdue | Pending | Jun 16, 2023 |
| 18256593 | COMPOSITIONS COMPRISING MOLECULES FOR CYSTIC FIBROSIS TREATMENT | NGUYEN, JOHN P | 1619 | §103§112 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18032768 | METHODS FOR IMPROVING PLANT GROWTH AND CROP YIELD BY USING COMPOUNDS OF TRISULPHIDE OR TETRASULPHIDE | PAK, JOHN D | 1699 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18031760 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | WESTERBERG, NISSA M | 1618 | §103 | Non-Final OA | 53d | Pending | Apr 13, 2023 |
| 18120204 | MICRORNA INHIBITOR SYSTEM AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §101§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18175371 | Forecasting method for flood crest magnitude and arrival time | LU, QIANG | 2187 | §101§103 | Final Rejection | — | Pending | Feb 27, 2023 |
| 18107108 | COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS | LEITH, NANCY J | 1636 | §103DP | Non-Final OA | — | Pending | Feb 08, 2023 |
| 17580129 | METHODS TO PREVENT, INHIBIT OR TREAT INTERVERTEBRAL DISC DEGENERATION | LEE, HOI YAN NMN | 1693 | §103 | Final Rejection | 5d overdue | Pending | Jan 20, 2022 |
| 17518301 | MULTIMODAL SENSORY STIMULATION | TRAN, JULIE THI | 3791 | §103 | Non-Final OA | 52d overdue | Pending | Nov 03, 2021 |
| 17503082 | MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS | REDDY, SUNITA | 3791 | §103§112 | Final Rejection | 5d | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Iowa Research Foundation has 17 pending office actions as of October 2026, spread across 13 art units and 16 examiners.
Celeste A Roney has the most, with 2 of University of Iowa Research Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
